173 related articles for article (PubMed ID: 27715904)
1. Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients.
Riggins DP; Cunningham CO; Ning Y; Fox AD
Subst Abus; 2017; 38(3):297-302. PubMed ID: 27715904
[TBL] [Abstract][Full Text] [Related]
2. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
[TBL] [Abstract][Full Text] [Related]
3. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
[TBL] [Abstract][Full Text] [Related]
4. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
[TBL] [Abstract][Full Text] [Related]
5. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
[TBL] [Abstract][Full Text] [Related]
6. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.
Bachhuber MA; Thompson C; Prybylowski A; Benitez J; Mazzella S; Barclay D
Subst Abus; 2018; 39(2):167-172. PubMed ID: 29474119
[TBL] [Abstract][Full Text] [Related]
7. Use of non-prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration.
Gryczynski J; Lee JD; Dusek K; McDonald R; Sharma A; Malone M; Monico LB; Cheng A; DeVeaugh-Geiss A; Chilcoat HD
J Subst Abuse Treat; 2021 Aug; 127():108349. PubMed ID: 34134866
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes.
Monico LB; Gryczynski J; Mitchell SG; Schwartz RP; O'Grady KE; Jaffe JH
J Subst Abuse Treat; 2015 Oct; 57():89-95. PubMed ID: 25986647
[TBL] [Abstract][Full Text] [Related]
9. Incarceration and compulsory rehabilitation impede use of medication for opioid use disorder and HIV care engagement in Vietnam.
King C; Cook R; Giang LM; Bart G; Hoffman K; Waddell EN; Korthuis PT
J Subst Abuse Treat; 2022 Mar; 134():108451. PubMed ID: 33962813
[TBL] [Abstract][Full Text] [Related]
10. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
11. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
12. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.
Connock M; Juarez-Garcia A; Jowett S; Frew E; Liu Z; Taylor RJ; Fry-Smith A; Day E; Lintzeris N; Roberts T; Burls A; Taylor RS
Health Technol Assess; 2007 Mar; 11(9):1-171, iii-iv. PubMed ID: 17313907
[TBL] [Abstract][Full Text] [Related]
13. [High-dose buprenorphine substitution during incarceration. Management of opiate addicts].
Revnaud-Maurupt C; Caer Y; Escaffre N; Gagneau M; Galinier A; Marzo JN; Meroueh F
Presse Med; 2005 Apr; 34(7):487-90. PubMed ID: 15902999
[TBL] [Abstract][Full Text] [Related]
14. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
15. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
[TBL] [Abstract][Full Text] [Related]
16. Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment.
Fox AD; Chamberlain A; Frost T; Cunningham CO
Subst Abus; 2015; 36(2):155-60. PubMed ID: 25837290
[TBL] [Abstract][Full Text] [Related]
17. A call to action: Contingency management to improve post-release treatment engagement among people with opioid use disorder who are incarcerated.
Klemperer EM; Evans EA; Rawson R
Prev Med; 2023 Nov; 176():107647. PubMed ID: 37499918
[TBL] [Abstract][Full Text] [Related]
18. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
Banta-Green CJ; Williams JR; Sears JM; Floyd AS; Tsui JI; Hoeft TJ
Drug Alcohol Depend; 2020 Feb; 207():107799. PubMed ID: 31865058
[TBL] [Abstract][Full Text] [Related]
19. Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration.
Cherian T; Lim S; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Rosner Z; MacDonald R; Lee JD
Drug Alcohol Depend; 2024 Jun; 259():111274. PubMed ID: 38643529
[TBL] [Abstract][Full Text] [Related]
20. Does incarceration influence patients' goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail.
Vail W; Faro E; Watnick D; Giftos J; Fox AD
Drug Alcohol Depend; 2021 May; 222():108529. PubMed ID: 33810909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
